250+ investors that invest in your industry and stage
Transportation
Gaming
Community
Proptech
FinTech
Biotech
Climate
Marketplace
Artificial intelligence
Energy
Hardware
Media (entertainment)
EdTech
Consumer
Health Care
Impact
Enterprise
Agriculture (agtech)
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Web3
Publishing
Clean Energy
Sporting Goods
Oil and Gas
B2B
Education
Organic Food
Big Data
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Video Games
Financial Services
Payments
Photography
Celebrity
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Franchise
Blockchain
Legal
Android
Social Impact
Mobile
Google
Construction
Sports
Local
eSports
Enterprise Software
Email
Wellness
Social Network
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Platforms
Biotechnology
Medical Device
Wine And Spirits
Automotive
Crowdfunding
Social
CleanTech
InsurTech
SaaS
Software
Film
Theatre
Life Science
Non Profit
Qatar
New Zealand
United States
South Korea
Germany
Australia
India
United Kingdom
Ireland
Canada
Africa
Asia
LATAM
Europe
Oceania
Middle East
China
South Africa
Singapore
Brazil
Japan
Indonesia
Sri Lanka
Vietnam
Spain
Saudi Arabia
Argentina
Armenia
Austria
Bangladesh
Bahrain
Belarus
Bulgaria
Belgium
Bermuda
Chile
Cameroon
Switzerland
Colombia
Belize
Costa Rica
Denmark
Ecuador
Algeria
Czech Republic
Georgia
Estonia
Egypt
Ghana
Hong Kong
Ethiopia
Gibraltar
Faroe Islands
Greece
Finland
Croatia
France
Hungary
Barbados
Kuwait
Italy
Jersey
Israel
Lebanon
Cambodia
Kenya
Cayman Islands
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Mali
Morocco
Norway
Malaysia
Mexico
Panama
Malta
Mauritius
Peru
Philippines
Nicaragua
Pakistan
Poland
Russian Federation
Romania
Sweden
Rwanda
Serbia
Seychelles
Turkey
Togo
Puerto Rico
Slovenia
Sierra Leone
San Marino
Senegal
Tunisia
Tanzania
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Thailand
Taiwan
Ukraine
Uruguay
Zimbabwe
Venezuela
Portugal
Azerbaijan
Bahamas
Guatemala
Iraq
Iceland
Namibia
Nigeria
United Arab Emirates
Honduras
Bolivia
Isle of Man
Luxembourg
Cyprus
Latvia
Oman
Angel investors
VC Funds
All investors
Download Find emails Save list

Top 5 Beauty Startup Investors in Switzerland in October 2023

A list of 5 angel investors and VC (Venture Capital) funds that invest in Beauty startups based in Switzerland. We rank investors based on the number of investments they made in Beauty companies from Switzerland. We update this investor list every month.

Top 5 Beauty Startup Investors in Switzerland in October 2023

Investor Beauty Switzerland investments
Ertan Wittwer 2
Yellowstone Holding 1
UZH Life Sciences Fund 1
Zürcher Kantonal Bank 1
Giammaria Giuliani 1

Get 300+ niche investors in 2 minutes.

Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.

Find investors — It's Free!

Trusted by 21,000+ founders from:

Y Combinator Techstars Antler Pioneer On Deck
Investor list
Ertan Wittwer
Angel · Munich, Bayern, Germany · 3 investments in the past 12 months

Ertan Wittwer is the Founder and Board Member bestsmile. He attended BBZ Uzwil.

Show more...

Investment focus

  • Health Care, Beauty, Dental
  • Seed, Angel, Pre-Seed
  • Switzerland

Portfolio highlights

  • Akina — Akina is developing the future of gamified digital healthcare to benefit individuals with chronic diseases around the world.
  • Noriware — Noriware wants to revolutionize the packaging industry by offering a truly sustainable, home-compostable alternative to traditional plastic, through unlocking the potential of seaweed. In doing so, we want to be the leader in transparency to motivate the industry to become more sustainable.
  • Alpine White — Alpine White is a healthcare startup that manufactures personal care products and treatments for its consumers. They exist to keep teeth healthy and white through great products and services that empower people to feel confident and feel good.
Show more investments...

Yellowstone Holding
VC Fund · 1 investment in the past 12 months

Yellowstone Holding promoting new innovative products or technologies from Switzerland to the Asia market via our strong connections.

Show more...

Investment focus

  • Beauty, Cosmetics, Navigation
  • Series A, Series B
  • Switzerland

Portfolio highlights

  • CUTISS — CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
  • Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
Show more investments...

UZH Life Sciences Fund
VC Fund · Zürich, Zurich, Switzerland

The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.

Show more...

Investment focus

  • Health Care, Biotechnology, Medical Device
  • Funding Round, Seed, Convertible Note
  • Switzerland

Portfolio highlights

  • Occlufit — Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.
  • Navignostics — Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Show more investments...

Zürcher Kantonal Bank
VC Fund · Zürich, Zurich, Switzerland · 17 investments in the past 12 months

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Show more...

Investment focus

  • Health Care, Medical Device, Biotechnology
  • Seed, Series A, Funding Round
  • Switzerland, Japan, Germany

Portfolio highlights

  • Helio — Carbon Aware Cloud Computing.
  • Tune Insight — Tune Insight orchestrates secure collaborations on sensitive data between multiple organizations to extract collective insights.
  • Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
Show more investments...

Giammaria Giuliani
Angel

Giammaria Giuliani

Show more...

Investment focus

  • Beauty, Cosmetics
  • Series A, Series B
  • Switzerland

Portfolio highlights

  • CUTISS — CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
Show more investments...
Investors by industry
Investors by country
Investors in Switzerland by industry

Close your round

Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.

Find investors — It's Free!

Join 21,000+ founders from:

Y Combinator Techstars Antler Pioneer On Deck